{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/fungal-nail-infection/prescribing-information/topical-amorolfine/","result":{"pageContext":{"chapter":{"id":"6780cd52-ecfd-5eba-8c7e-66bc71b64ed2","slug":"topical-amorolfine","fullItemName":"Topical amorolfine","depth":2,"htmlHeader":"<!-- begin field 42403702-0a1c-4d9a-a338-c7500a67325b --><h2>Topical amorolfine</h2><!-- end field 42403702-0a1c-4d9a-a338-c7500a67325b -->","summary":"","htmlStringContent":"<!-- begin item b57e1758-2db4-429d-a479-dda9ccb70888 --><!-- end item b57e1758-2db4-429d-a479-dda9ccb70888 -->","topic":{"id":"1303927b-7e0c-517d-85e9-841c9ac02151","topicId":"d2c6135f-fef1-4a56-80dc-161c93380c7d","topicName":"Fungal nail infection","slug":"fungal-nail-infection","lastRevised":"Last revised in March 2018","chapters":[{"id":"bc563964-f1b0-559d-9f21-380162710ddf","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"dd347390-fb63-5e80-9fab-bd3cc4704341","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0cdd100c-c9d0-5685-980c-52f246d1100e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"886d32db-68df-5055-b459-55404c1f011e","slug":"changes","fullItemName":"Changes"},{"id":"c1cacd2b-dba0-5341-a274-66fd882b2036","slug":"update","fullItemName":"Update"}]},{"id":"9f0a65a3-9309-5a00-a9fa-bda2fb7a49c4","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1121797b-5555-5e24-a9ae-aabc657725dd","slug":"goals","fullItemName":"Goals"},{"id":"aa660497-e222-5e9d-b282-3069500c380f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"49df22af-d1aa-56cd-b2dc-30e6ecc84ca8","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a79a5fd4-4f6a-5d37-8714-e4bd3bea76b0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6db25a8b-db82-5b72-bade-fa216c349fd8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2515b15e-47ac-5e93-acaf-588daa2e06f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d257da5b-218f-50fc-96b1-55ec4b44f5cd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7ccd879d-9979-5f0b-b655-8da37ca04149","slug":"definition","fullItemName":"Definition"},{"id":"20d20421-b2ba-513f-87b5-3fad4f731aa5","slug":"causes","fullItemName":"Causes"},{"id":"3142330a-0287-5835-8a69-857972828fb2","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"29b083db-9488-5407-92df-43f4952d8df3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d7dd4e0b-6a97-5db7-bfa3-aa690c7974af","slug":"complications","fullItemName":"Complications"},{"id":"3a29be3f-ea9f-56a3-b8d7-78341665856e","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4346dd42-e5eb-550e-a004-7c8e7103a196","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b6a7486c-a6d8-5d8b-918c-8610bf76e212","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"eec0a81e-c0c0-5f9d-951e-f19c41cfafaf","slug":"assessment","fullItemName":"Assessment"},{"id":"d84aa70d-b236-5783-9eeb-e1181b1311f8","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"12363e3a-9d3f-54c7-8f68-1145b8f312b3","fullItemName":"Management","slug":"management","subChapters":[{"id":"36068044-ec28-5f59-b737-dd89aa53cca5","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"94da5137-b65a-5fa1-a933-bbcaa1a5c10b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"6780cd52-ecfd-5eba-8c7e-66bc71b64ed2","slug":"topical-amorolfine","fullItemName":"Topical amorolfine"},{"id":"7009ace0-8da0-5da4-917e-8900ae3cc390","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"5d413d25-a998-5ee4-ad9d-be6306400282","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"}]},{"id":"0b102b3a-ebce-5c6e-9670-3610defc871d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bc0bd4bc-1b10-52dc-b942-cd4682774d01","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"dc202e28-37b1-5789-a14a-b5a0850d8cf8","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"49993e8c-ae7a-5891-bf43-21a6406ce1b5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b6aa45b7-d833-599f-8bcc-4d08c6c264bb","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2805cbb7-09b5-5875-a0c1-c501223c6ab3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"595745a2-d654-5e3b-850e-eac6532bd5db","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"74af204e-7571-5d05-963f-0c0614335fbf","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"94da5137-b65a-5fa1-a933-bbcaa1a5c10b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"875d318e-bb5f-5f1a-af24-9b2e1245bd75","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 9dcf1fe5-dbea-4415-886d-a89a00f75451 --><h3>Contraindications and cautions</h3><!-- end field 9dcf1fe5-dbea-4415-886d-a89a00f75451 -->","summary":"","htmlStringContent":"<!-- begin item 4b10eeb3-cf83-44d8-9b98-a89a00f752a7 --><!-- begin field 4ac50df4-6f03-4bd7-90cb-a89a00f75451 --><ul><li>Advise people using topical amorolfine nail lacquer to avoid contact with the ears, eyes, and mucous membranes.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">BNF 75, 2018</a>] </p><!-- end field 4ac50df4-6f03-4bd7-90cb-a89a00f75451 --><!-- end item 4b10eeb3-cf83-44d8-9b98-a89a00f752a7 -->","subChapters":[]},{"id":"84edaa00-7abf-55bd-8d7f-7c28044350cb","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 4cb1f831-8165-40b7-89b6-a89a00f7a78a --><h3>Adverse effects</h3><!-- end field 4cb1f831-8165-40b7-89b6-a89a00f7a78a -->","summary":"","htmlStringContent":"<!-- begin item ae9d335d-0a9f-4059-8628-a89a00f7a634 --><!-- begin field d8b29118-eb06-4659-8bda-a89a00f7a78a --><ul><li>Advise people applying topical amorolfine nail lacquer that a burning sensation, erythema, hypersensitivity reactions, itching, and occasional local irritation may occur after application.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">BNF 75, 2018</a>] </p><!-- end field d8b29118-eb06-4659-8bda-a89a00f7a78a --><!-- end item ae9d335d-0a9f-4059-8628-a89a00f7a634 -->","subChapters":[]},{"id":"a497a867-291a-5b4f-9112-8f44e4403748","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field aa4388a0-598d-4f56-9642-a89a00f7ba7e --><h3>Drug interactions</h3><!-- end field aa4388a0-598d-4f56-9642-a89a00f7ba7e -->","summary":"","htmlStringContent":"<!-- begin item 734f3dcf-d232-4209-9ea2-a89a00f7b92c --><!-- begin field e6ca8541-1a96-4e5f-87d1-a89a00f7ba7e --><ul><li>No drug interaction studies have been performed regarding the use of topical amorolfine nail lacquer.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">ABPI Medicines Compendium, 2013</a>] </p><!-- end field e6ca8541-1a96-4e5f-87d1-a89a00f7ba7e --><!-- end item 734f3dcf-d232-4209-9ea2-a89a00f7b92c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}